- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
CVSG
LSE
Week ended 07 Aug 2026
Weekly Investor Report
CVS Group plc · Healthcare · Medical Care Facilities
Latest close
1,300 GBP
3.8%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 4.5% above the Trend Line and sits at 40.6% of its 52-week range. The latest completed week returned 3.8%, after a 5.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100.
Setup score
48
out of 100
Latest Close
1,300 GBP
7 Aug 2026
1W Return
3.8%
latest completed week
4W Return
5.2%
short-term follow-through
12W Return
10.5%
quarterly tape
Trend Breadth
44.2%
23 of 52 weeks active
Volume Ratio
1.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.8%
Latest completed week; four-week move 5.2%.
Indicator stack
24/89
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
9 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 4.5% above the Trend Line and sits at 40.6% of its 52-week range. The latest completed week returned 3.8%, after a 5.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2712-week average 0.15
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.27Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 5.2% over four weeks, 10.5% over 12 weeks, and 7.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year23
Trend breadth44.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.79Latest activity-pressure read.
Pressure change304.0%Four-week change in activity pressure.
Leadership-4.12Latest relative-leadership reading.
RS change35.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 42%
Model confidence 34%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength76/100Blend of value, momentum, and quality. Underlying universe rank 25; rank 1 is best.
Value68/100Relative valuation strength. Underlying universe rank 33; rank 1 is best.
Quality69/100Profitability and accounting quality. Underlying universe rank 32; rank 1 is best.
Momentum69/100Medium-term price momentum. Underlying universe rank 32; rank 1 is best.
Growth69/100Revenue and earnings growth. Underlying universe rank 32; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- - Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 0/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.7% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.7% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- - Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 9 relevant articles.
1 positive · 8 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-21.1%Distance below the 52-week high.
13-week volatility3.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2612 weeks finished lower.
Best week+7.0%Week of 17 Apr.
Worst week-7.5%Week of 20 Mar.
Latest week+3.8%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains8
Flat weeks1
Modest losses7
Sharp losses5
Recent vol3.6%13-week weekly-return volatility.
Base vol3.9%52-week weekly-return volatility.
Up/down split29/22Count of positive and negative weeks in the 52-week window.
Average skew3.0% / -3.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGB Healthcare
4-week rank25 / 79
Group average0.0%
Trend breadth27.8%
Trend27.8%active weekly trend signals
MD44.3%positive activity pressure
RS22.8%positive relative leadership
Four-week leaders
IndustryGB Medical Care Facilities
4-week rank3 / 3
Group average9.5%
Trend breadth66.7%
Trend66.7%active weekly trend signals
MD100.0%positive activity pressure
RS66.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape45/100
Trend, activity pressure, participation, and risk combine to a 45/100 tape read.
Indicator analysis24/100Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 0/12.
Activity pressure 0.27; No reversal markers Factors70/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 53; Small Cap Core rank 50 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 9 relevant articles.
CVS Group plc (CVSG) Announces Updated Total Voting Rights of 68,442,787 Shares Following Buyback Share Cancellations Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1,300 GBP | 3.8% | 1,244 GBP | 1,227 GBP | 0.79 | -4.12 | 1.0M | Off |
| 31 Jul 2026 | 1,252 GBP | 4.7% | 1,246 GBP | 1,232 GBP | 0.70 | -7.58 | 1.5M | Off |
| 24 Jul 2026 | 1,196 GBP | -6.9% | 1,247 GBP | 1,237 GBP | 0.59 | -10.87 | 2.2M | Off |
| 17 Jul 2026 | 1,284 GBP | 3.9% | 1,249 GBP | 1,242 GBP | 0.47 | -3.48 | 1.3M | Off |
| 10 Jul 2026 | 1,236 GBP | -0.6% | 1,248 GBP | 1,247 GBP | 0.20 | -6.39 | 958.9K | Off |
| 3 Jul 2026 | 1,244 GBP | 5.3% | 1,248 GBP | 1,251 GBP | 0.06 | -7.62 | 228.7K | Off |
| 26 Jun 2026 | 1,181 GBP | 0.1% | 1,247 GBP | 1,255 GBP | -0.04 | -11.15 | 175.2K | Off |
| 19 Jun 2026 | 1,180 GBP | -4.1% | 1,248 GBP | 1,260 GBP | -0.09 | -10.40 | 354.8K | Off |
| 12 Jun 2026 | 1,231 GBP | -0.9% | 1,248 GBP | 1,266 GBP | -0.24 | -7.91 | 334.7K | Off |
| 5 Jun 2026 | 1,242 GBP | -0.7% | 1,245 GBP | 1,272 GBP | -0.45 | -6.51 | 536.7K | Off |
| 29 May 2026 | 1,251 GBP | 4.3% | 1,244 GBP | 1,277 GBP | -0.68 | -6.57 | 1.6M | Off |
| 22 May 2026 | 1,199 GBP | 2.0% | 1,243 GBP | 1,283 GBP | -0.87 | -11.22 | 860.7K | Off |
| 15 May 2026 | 1,176 GBP | 4.4% | 1,249 GBP | 1,289 GBP | -0.92 | -10.97 | 1.4M | Off |
| 8 May 2026 | 1,126 GBP | -3.8% | 1,256 GBP | 1,295 GBP | -0.94 | -15.43 | 1.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.